• Asian Pacific Journal of Cancer Prevention
• /
• 제15권6호
• /
• pp.2771-2776
• /
• 2014

Background: Breast cancer screening and higher quality mammography have resulted in an increase in the diagnosis of ductal carcinoma in situ worldwide. We compared the incidence and other factors in our cases of ductal carcinoma in situ between two recent decades. Materials and Methods: Medical records of cases of ductal carcinoma in situ who had been admitted to the surgery wards of the Cancer Institute of Tehran, Iran were evaluated from March 1993 to March 2003 as phase 1, and from April 2003 to April 2013 as phase 2. Results: Ratio of ductal carcinoma in situ to overall breast cancer was 1.27 and 3.93 in phases 1 and 2, respectively. Rates of excisional or incisional biopsies versus core needle biopsies and clinically versus mammographically detected cases as well as median size of tumors dropped between the 2 phases while a substantial rise in the number of patients attending for screening was seen in this time period. Surgical treatments followed a trend from modified radical mastectomy and axillary lymphatic dissection toward breast conserving surgery and sentinel node dissection or no axillary intervention. Conclusions: Our study shows a considerable trend toward earlier detection of breast cancer and evolution of treatment strategies toward standard less invasive surgery of DCIS in Iran.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권8호
• /
• pp.3733-3736
• /
• 2016

HER2/neu is a well-established prognostic and predictive factor for invasive breast cancer. However, the role of HER2/neu in ductal breast carcinoma in situ (DCIS) is debated and recent data have suggested that it is mainly linked to in situ local recurrence. Although molecular data suggest that atypical ductal hyperplasia (ADH) and duct carcinoma in situ (DCIS) are related lesions, albeit with vastly different clinical implications, the role of HER2/neu expression in atypical ductal hyperplasia is not well defined either. The aim of this study was to evaluate over expression of HER2/neu in DCIS and cases of ADH in comparison with invasive breast carcinoma. Archival primary breast carcinoma paraffin blocks (n=15), DCIS only (n=10) and ductal epithelial hyperplasia and other breast benign lesions (n=25) were analyzed for HER2/neu immunoexpression. Follow up was available for 40% of the patients. HER2/neu was positive in 80%of both DCIS and invasive carcinoma, and 67% of atypical ductal hyperplasia (ADH) cases. Thus at least a subset of patients with preinvasive breast lesions were positive, which strongly suggests a role for Her2/neu in identifying high-risk patients for malignant transformation. Although these are preliminary data, which need further studies of gene amplification within these patients as well as a larger patient cohort with longer periods of follow up, they support the implementation of routine Her2/neu testing in patients diagnosed as pure DCIS and in florid ADH.

• Korean Journal of Radiology
• /
• 제25권8호
• /
• pp.698-705
• /
• 2024

Ductal carcinoma in situ (DCIS) accounts for approximately 30% of new breast cancer diagnoses. However, our understanding of how normal breast tissue evolves into DCIS and invasive cancers remains insufficient. Further, conclusions regarding the mechanisms of disease progression in terms of histopathology, genetics, and radiology are often conflicting and have implications for treatment planning. Moreover, the increase in DCIS diagnoses since the adoption of organized breast cancer screening programs has raised concerns about overdiagnosis and subsequent overtreatment. Active monitoring, a nonsurgical management strategy for DCIS, avoids surgery in favor of close imaging follow-up to de-escalate therapy and provides more treatment options. However, the two major challenges in active monitoring are identifying occult invasive cancer and patients at risk of invasive cancer progression. Subsequently, four prospective active monitoring trials are ongoing to determine the feasibility of active monitoring and refine the patient eligibility criteria and follow-up intervals. Radiologists play a major role in determining eligibility for active monitoring and reviewing surveillance images for disease progression. Trial results published over the next few years would support a new era of multidisciplinary DCIS care.

• 대한영상의학회지
• /
• 제83권4호
• /
• pp.898-903
• /
• 2022

선별 유방촬영술이 널리 사용됨에 따라 관상피내암의 빈도는 증가해왔다. 뿐만 아니라, 이의 발견에 있어서는 자기공명영상이 유방촬영술보다 더 높은 민감도를 가진다. 이에 저자들은 침윤성 유방암에 동반된 광범위한 범위의 관상피내암의 비정형적인 자기공명영상 소견을 소개하고자 한다.

• 대한세포병리학회지
• /
• 제11권2호
• /
• pp.75-81
• /
• 2000

Cathepsin D is a protease which is known to facilitate invasion and metastasis of breast carcinoma. Overexpression of cathepsin D is associated with poor clinical outcome and biologic aggressiveness of the breast cancer. We underwent immunocytochemical assay(ICA) for cathepsin D in fine needle aspiration cytology(FNAC) specimens from the breast carcinoma and benign breast diseases. In FNAC specimens cathepsin D was expressed in 21(42.9%) out of 49 cases of invasive ductal carcinoma, whereas negative result was observed in all 15 cases of benign breast diseases including 7 fibroadenomas, 6 fibrocystic diseases, and 2 benign ductal hyperplasias. Among the 11 FNAC specimens from ductal carcinoma in situ(DCIS), cathepsin D was expressed in 3 cases(27.3%). In FNAC specimens immunocytochemistry for cathepsin D showed positive result in 24 out of 60 carcinomas(sensitivity, 40%) and negative result in 15 out of all 15 benign breast diseases(specificity, 100%). No significant correlation was noted between cathepsin D expression in FNAC specimen and clinicohistological characteristics of the breast carcinoma, such as hormone receptors and cell differentiation. In conclusion, ICA of cathepsin D in FNAC specimens thought to be a good adjunct to differentiate malignancy from benign breast diseases.

• Investigative Magnetic Resonance Imaging
• /
• 제19권2호
• /
• pp.127-130
• /
• 2015

Direct injection of foreign material, such as liquid paraffin and silicone, into the breast can induce a foreign body granulomatous reaction and fibrosis, resulting in hard, nodular breast masses and architectural distortion that can mimic neoplasm. Conventional methods, including physical examination, mammography, and ultrasonography are of little use to differentiate between foreign body-induced mastopathy and breast cancer. In patients with foreign body injection such as breast augmentation, dynamic contrast enhanced MR imaging is an excellent imaging modality. Here, the authors report the MR imaging and pathological findings of ductal carcinoma in situ (DCIS) with multicystic changes in a 41-year-old woman with a previous history of interstitial mammoplasty by paraffin injection.

• 핵의학기술
• /
• 제18권1호
• /
• pp.140-144
• /
• 2014

최근 유방암 환자의 급증은 여러 가지 통계로 보고되고 있다. 유방암의 발병부위는 크게는 유관, 소엽등으로 분류하고 그 중 85% 이상이 유관에서 발병되고 있다. 본 연구는 유관에서 발병되는 암의 종류를 분별하여 시간의 경과에 따라 변화되는 $SUV_{max}$의 차이를 알아보고자 하였다. 2012년 7월 1일부터 2013년 7월 22일까지 유방암 진단을 받고 본원 PET-CT센터를 방문한 여성 환자 291명을 대상으로 하였다. 병리학적 결과를 기준으로 IDC (invasive ductal carcinoma) 환자 248명과 DCIS (ductal carcinoma in situ) 환자 43명을 선별하였다. 일반 PET-CT 검사와 동일한 방법(3.7 MBq/kg)으로 $F^{18}-FDG$를 주사 후 1시간 경과 후 1차 검사(routine 검사)를 진행하였고 또 한 번의 1HR 경과 후 2차 검사 (Delay검사)를 진행하였다. 2회 진행된 검사 Data를 토대로 하여 병소부위에 ROI를 설정하여 $SUV_{max}$를 측정하였다. IDC와 DCIS의 두집단의 병소 $SUV_{max}$의 변화를 비교 확인한 결과 IDC의 경우 $SUV_{max}$값이 1차 검사에서는 M=7.11, SD=5.405이고 2차 검사에서는 M=8.363, SD=6.624으로 상승(P<0.05)하였으며, DCIS의 경우 $SUV_{max}$는 1차 검사에서는M=2.739, SD=1.229이고 2차 검사에서는 M=2.614, SD=1.470으로 감소(P<0.05)하였다. 결 론: IDC와 DCIS의 시간에 따른 $SUV_{max}$의 결과를 비교해본 결과 IDC에서는 1차 검사(routine검사)보다 2차 검사(Delay검사)에서 $SUV_{max}$가 상승(P=0.000)함을 확인하였고 DCIS에서는 1차 검사(roution검사)보다 2차 검사(Delay검사)에서 $SUV_{max}$값이 감소(P=0.039)함을 확인하였다. 본 연구를 통해 유관에서 발병되는 유방암의 종류(IDC와 DCIS)별 시간경과에 따라 $SUV_{max}$의 변화가 발생함을 확인하였다.

• Applied Microscopy
• /
• 제51권
• /
• pp.6.1-6.9
• /
• 2021

Histopathology is a well-established standard diagnosis employed for the majority of malignancies, including breast cancer. Nevertheless, despite training and standardization, it is considered operator-dependent and errors are still a concern. Fractal dimension analysis is a computational image processing technique that allows assessing the degree of complexity in patterns. We aimed here at providing a robust and easily attainable method for introducing computer-assisted techniques to histopathology laboratories. Slides from two databases were used: A) Breast Cancer Histopathological; and B) Grand Challenge on Breast Cancer Histology. Set A contained 2480 images from 24 patients with benign alterations, and 5429 images from 58 patients with breast cancer. Set B comprised 100 images of each type: normal tissue, benign alterations, in situ carcinoma, and invasive carcinoma. All images were analyzed with the FracLac algorithm in the ImageJ computational environment to yield the box count fractal dimension (Db) results. Images on set A on 40x magnification were statistically different (p = 0.0003), whereas images on 400x did not present differences in their means. On set B, the mean Db values presented promising statistical differences when comparing. Normal and/or benign images to in situ and/or invasive carcinoma (all p < 0.0001). Interestingly, there was no difference when comparing normal tissue to benign alterations. These data corroborate with previous work in which fractal analysis allowed differentiating malignancies. Computer-aided diagnosis algorithms may beneficiate from using Db data; specific Db cut-off values may yield ~ 99% specificity in diagnosing breast cancer. Furthermore, the fact that it allows assessing tissue complexity, this tool may be used to understand the progression of the histological alterations in cancer.

• 한국방사선학회논문지
• /
• 제17권5호
• /
• pp.743-749
• /
• 2023

유방의 관상피내암(DCIS; ductal carcinoma in situ)은 유방의 상피세포가 악성화되었지만, 아직 정상적인 유관에 한정되어 있는 경우를 지칭하며, 최근 빠르게 증가하고 있다. 본 증례에서 추적관찰 2년 동안은 유방 촬영술 및 초음파 검사상 병변은 BI-RADS Category 3으로 분류되는 작은 mass가 관찰되었지만 낭성 mass 소견을 보여, 전형적인 악성 종양의 소견과는 거리가 있었으나 추적관찰 2년째에 유방초음파상 우측 유방 6시 방향에 불분명한 경계(Lobulated margin)를 보이는 저에코(hypoechoic) 종괴가 약 2.1 × 1.3 cm 크기로 보였으며 조직 검사상 관상피내암으로 진단되었다. 관상피내암은 특징적인 임상소견이 없고 초기에 양성의 임상, 영상 소견을 보일 수 있으므로 정기적인 추적관찰을 시행하는 것이 조기 진단에 중요할 것으로 사료되며, 유방촬영술과 초음파 검사로 관상피내암을 발견하는 것은 유방암 환자 전체의 예후를 좋게 하는 데에 중요하다고 할 수 있겠다. 4년 전 처음 검사 시 증상이 없으며 유방촬영상 정상이고 유방초음파상 악성 징후 없는 낭성병변이 추적관찰 중에 관상피내암의 소견인 비대칭 음영과 미세석회화, 분엽상의 mass가 관찰된 관상피내암의 증례를 보고한다.

• Journal of Preventive Medicine and Public Health
• /
• 제31권4호
• /
• pp.592-603
• /
• 1998

This study was conducted to estimate incidence rate of female breast cancer in a defined area of Chungchongbuk-do in Korea. The presumptive breast cancer cases were selected from two different sources, i.e., medical utilization database of the National Health Insurance Corporation and the database from the National Cancer Registry. Medical students visited each hospital where the presumptive cases had been treated as a breast cancer patient, and made a dictation of medical record of each patient based on the claims stored in the Insurance Corporation from January to December 1995. The diagnoses in the claims included one of the following diagnostic codes; ICD-9 174-175(malignant neoplasms of the breast), 233(carcinoma in situ of the breast and genito-urinary system)or ICD-10 C50(malignant neoplasms of the breast), D05(carcinoma in situ of the breast and genito-urinary system). Each case has been confirmed as having a breast cancer by a breast surgeon through a medical record review. Age-standardized incidence rate of female breast cancer to the Korean population was estimated to be 10.5(95%confidence interval : 8.1-12.9)per 100,000 persons in 1995. Age-standardized rate to the world population was 9.8 per 100,000 persons, and the truncated rate for ages 35-64 was 27.2 per 100,000 persons. Validity of these estimates is discussing in comparison with previous methods of incidence estimation in Korea.